Aligos Therapeutics stock rallied sharply in after-hours trading after the company announced it had received a $25 million upfront cash payment from Xiamen Amoytop Biotech Co., Ltd. The payment was made under an exclusive license that gives Amoytop the right to develop and commercialize pevifoscorvir sodium in Greater China for the treatment of chronic hepatitis B virus infection.
Under the terms disclosed, the deal also makes Aligos eligible to collect up to $420 million more in payments tied to clinical, regulatory, and sales milestones. In addition, Amoytop will pay Aligos tiered royalties in the high single digits on net sales within the licensed territories.
Financial and operational implications
Company statements accompanying the announcement highlighted the immediate cash benefit as well as a material extension of Aligos’ financial runway. Management indicated that the infusion of proceeds is expected to extend the company’s cash runway into the fourth quarter of 2026, an outcome that eases near-term liquidity pressures for the clinical-stage firm.
Importantly for shareholders, Aligos retains full development and commercialization rights for pevifoscorvir sodium in the United States, Europe, Japan, South Korea, and all other markets outside Greater China. The company also preserved its right to run clinical trials in Greater China, maintaining an operational foothold in the region even as commercial rights there pass to Amoytop.
Clinical program timing
The licensing announcement comes while Aligos is advancing the Phase 2 B-SUPREME study of pevifoscorvir sodium, which is testing the drug against the standard-of-care antiviral tenofovir disoproxil fumarate. The trial is approaching a second interim data readout that is expected in the second half of 2026.
Market reaction and context
Shares of Aligos reacted strongly to the news, jumping nearly 19.9% in after-hours trading. Intraday quotes in the release noted an after-hours print of $6.99 reflecting roughly a 19.49% move, and the company’s stock was cited at $7.014 following the close, up from a regular-session reference of $5.85.
The announcement coincided with a broadly constructive day for U.S. equities, with the Nasdaq Composite up 1.1% and the S&P 500 higher by 0.7% on the same trading day. Analyst coverage ahead of the news had been generally favorable, with several firms including H.C. Wainwright, Cantor Fitzgerald, Piper Sandler, and Lake Street carrying Buy or equivalent ratings on the stock.
What this means
The combination of an immediate cash payment, potentially significant milestone and royalty upside from Greater China, and the preservation of development and commercial rights across major Western markets prompted a re-evaluation of Aligos’ near-term prospects by investors. The company’s ability to continue clinical activity in Greater China while monetizing regional commercial rights formed a central element of the market’s response.
Looking ahead, the timeline for the Phase 2 program’s second interim readout in the second half of 2026 and the contingent milestone payments embedded in the Amoytop agreement will be key drivers of how the deal affects Aligos’ valuation over time.